Vodafone and Three will have to wait longer for approval of their £15bn planned merger from the UK’s competition regulator.
4d Pharma PLC (AIM:DDDD) Cancellation of admission to trading on AIM
Leeds, UK, 15 February 2023 – 4D pharma plc (the “Company”) (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class
4d Pharma PLC (AIM:DDDD) Updated Results from Renal Cell Carcinoma Cohort
4D pharma Announces Updated Results from the Renal Cell Carcinoma Cohort of the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab)
4d Pharma PLC (AIM:DDDD) Update on Administration and Suspension of Trading
Leeds, UK – December 30, 2022 – 4D pharma plc (AIM: DDDD) (in administration), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived
4d Pharma PLC (AIM:DDDD) Blautix Phase II Clinical Trial Results Published
4D pharma’s Blautix® Phase II Clinical Trial Results Published in Alimentary Pharmacology & Therapeutics
4d Pharma PLC (AIM:DDDD) MRx0518 poster presentations at SITC 2022
4D pharma Announces Two Presentations at The Society for Immunotherapy of Cancer Annual Meeting (SITC 2022)
4d Pharma PLC (AIM:DDDD) Update on Suspension of Trading on AIM – Delay to publication of Interim Results
Leeds, UK, September 28, 2022 , – 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from
4d Pharma PLC (AIM:DDDD) Publication of preclinical autism research
4D pharma Announces Publication of Preclinical Research Showing Live Biotherapeutic MRx0006 Efficacy in Animal Model of Autism Spectrum Disorder
4d Pharma PLC (AIM:DDDD) Temporary Suspension
Leeds, UK, 24 June 2022 , – 4D pharma plc (AIM: DDDD, Nasdaq LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug
4d Pharma PLC (AIM:DDDD) ASCO 2022 MRx0518 and Bavencio Trial In Progress
4D pharma Presents Trial in Progress Poster on the Phase II Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the
4d Pharma PLC (AIM:DDDD) ATS 2022 – MRx-4DP0004 Phase I/II Part A poster
4D pharma Presents Late-Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International Conference
4d Pharma PLC (AIM:DDDD) Final Results
4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022